FDA delays decision on Orexigen's obesity drug by three months

Reuters: Orexigen Therapeutics Inc said the U.S. Food and Drug Administration delayed a decision on the marketing application for its obesity drug, contrave, by three months, sending the company's shares down as much as 20 percent on Wednesday.

The FDA indicated that the extension was needed to reach agreement on packaging and other post-marketing obligations related to the evaluation of potential heart risks associated with the drug, Orexigen said.

Read article